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SUMMARY
A HUVEC cDNA library was screened with sera from two patients who had developed transplant-
associated coronary artery disease (TxCAD) following cardiac transplantation. A total of six positive
clones were isolated from a primary screen of 40 000 genes. Subsequent DNA sequence analysis
identified these to be lysyl tRNA synthetase, ribosomal protein L7, ribosomal protein L9, b transducin
and TANK. Another gene whose product could not be identified showed homology to a human cDNA
clone (DKFZp566M063) derived from fetal kidney. Full-length constructs of selected genes were
expressed as his-tag recombinant fusion proteins and used to screen a wider patient base by ELISA to
determine prevalence and association with TxCAD. Of these ribosomal protein L7 showed the highest
prevalence (55·6%) with TxCAD sera compared to 10% non-CAD.
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INTRODUCTION
Transplant-associated coronary artery disease (TxCAD) is the
most common long-term complication following cardiac trans-
plantation. The condition is characterized by the concentric
narrowing of the major epicardial and intramyocardial coronary
arteries and veins [1] due primarily to the secretion of
extracellular matrix components by activated smooth muscle cells
[2–4]. The lesion components are generally bland compared to the
calcified typical atherosclerotic plaque and endothelium is usually
intact, although may appear plump [1]. The assessment of TxCAD
is normally undertaken by routine angiography and classified as
positive if 25% or greater luminal thickening affects one or more
epicardial arteries.
Subendothelial leucocytes, predominantly macrophages, may
be seen (endothelialitis), although their number is usually sparse
compared to that seen in acute rejection [5] where T cells
predominate [6]. It has been proposed that the proliferation of the
intima may be a consequence of immune-mediated endothelial
activation and/or damage inducing the release of cytokines and
growth factors causing smooth muscle cell proliferation and
secretion of extracellular matrix components [7–12].
The appearance of antibody reactivities to donor HLA
antigens following transplantation has been found to be associated
with an increased risk of developing TxCAD [13–17]. The
possibility that non-HLA antiendothelial cell antibodies (AECA)
may contribute to the development of TxCAD by either activating
the endothelium to release SMC growth factors or causing
endothelial cell damage and subsequent release of growth factors
has been addressed. These studies have identified the appearance
of antibodies reactive to a variety of antigens present in
endothelial cell lysates associated with the development of early
TxCAD (, 5 years) and identified vimentin, HSP60, 75 kDa
glucose-regulated protein and triose phosphate isomerase as
candidate TxCAD specific antigens by 2D-SDS PAGE [18–20].
Currently an ELISA to detect antivimentin antibodies has been
developed [21] which shows a correlation with the development of
TxCAD [22]. Although these studies identified cytosolic antigens,
a clear association between the development of antiendothelial
cell surface antigens following transplantation and the develop-
ment of TxCAD has also been observed [23].
The possible involvement of antibodies recognizing antigens
other than classical MHC determinants in graft deterioration is
hampered by a full description of which reactivities may occur
postoperatively. Furthermore, the possibility that pathogenic
antibodies present prior to transplantation may contribute to the
failure of the host’s own organ and accelerate the development of
TxCAD in the allograft complicates the issue. Elucidation of their
possible role in pathology requires the identification of the range
of target antigens to which antibody formation may occur,
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enabling serological investigation to determine the prevalence and
association of these candidates with TxCAD.
In order to describe the immunoreactive profile of AECA in
chronic rejection more fully we have undertaken a limited screen
of a HUVEC cDNA expression library in an attempt to elucidate
which antibody specificities may be associated with TxCAD.
MATERIALS AND METHODS
A commercially available HUVEC cDNA library (Uni-ZAP XR,
Stratagene) was used to screen for clones showing immunor-
eactivity with TxCAD sera. The library was generated from a pool
of four HUVEC donors and RNA isolated at passage four.
Selection of sera for immunoscreening the expression library
Patient 1 was a 51-year-old male diagnosed with ischaemic heart
disease prior to transplantation and suffered one rejection episode
in the first year. He was mismatched for donor HLA at HLA-A
(1), HLA-B (2), HLA-DR (1). Serum was collected at
5 years post-transplant, at which time he had 50% coronary
arterial stenosis and a vimentin titre of 1/1000. Patient 2 was a 23-
year-old male diagnosed with cardiomyopathy prior to transplan-
tation and suffered two rejection episodes in the first year. He was
mismatched for donor HLA at HLA-A (2), HLA-B (2), HLA-
DR (1). Serum was collected at 2 years post-transplant, at which
time he had 50% coronary arterial stenosis and a vimentin titre of
1/400.
Sera were diluted 1/200 in PBS/5% milk/0·1% Tween-20/1%
BSA supplemented with 0·02% sodium azide. To reduce non-
specific binding to Escherichia coli (XL1 blue MRF 0) and phage
vector, diluted sera were pre-adsorbed 3 on non-recombinant
lifts (see below) for 1 h. Pre-adsorbed sera was then stored at 48C
and used within 6 months.
Primary immunoscreening
For primary immunoscreening the library was plated out at 10 000
pfu/140 mm plate using XL1 blue MRF 0 host cells according to
the supplier’s instructions. For detection of immunoreactive
clones two lifts were taken from separate plates for each serum.
Briefly, Duralon UV membranes (Stratagene) were soaked in
methanol, rinsed with PBS and incubated with 10 mm IPTG for 20
minutes and air-dried. Membranes were then overlaid onto the
plates and incubated for 3 h at 378C, after which they were
carefully removed after marking their orientation, washed with
PBS to remove excess agar and blocked for 2 h in 5% milk/PBS.
Pre-adsorbed sera was then added to the membranes and
incubated at 378C for 1 h at RT with gentle agitation. Following
this, sera was retained and membranes washed four times with
PBS/0·2% Tween-20 over 20 minutes. Bound antibody was
detected using 1/1000 dilution of HRP conjugated rabbit antihu-
man IgA, IgG, IgM (Dako) in PBS/5% milk/0·1% Tween-20 for a
further hour at RT with gentle agitation. Following a final four
washes in PBS/0·2% Tween-20 over 20 minutes membranes were
incubated with 4CN colour detection system (DuPont). Positive
immunoreactive plaques were readily visible and easily distin-
guished from blue non-recombinants. Plaques corresponding to
immunoreactive regions were cored from the original plate and
resuspended in SM buffer containing 10 m l chloroform.
Secondary screening
Positive colonies identified from the primary immunoscreen were
titred to between 100 and 500 pfu/140 mm plate and lifts taken as
described above. A further three rounds of immunoscreening were
sufficient to screen plaques to clonality.
Subcloning and identification of positive inserts
Cloned phage showing immunoreactivity was recovered as
pBluescript by single-stranded rescue using the ExAssist (Strata-
gene) filamentous helper phage according to the supplier’s
instructions and used to transform SolR cells. Positive recombi-
nants were then picked and grown overnight in 5 ml LB and
plasmid DNA isolated using the Wizard SV miniprep system
(Promega). DNA sequencing was conducted at the Molecular
Biology Unit, King’s College London.
Flanking vector sequences were identified and removed from
the database query file and the remaining insert DNA submitted to
a BLAST search using the GCG Wisconsin package at the HGMP
resource centre, MRC.
Recombinant protein
Recombinant His-tag fusion proteins were constructed by PCR-
based methods from total RNA isolated from primary HUVEC
cultures at passage four using RNEasy (Quiagen). For selected
candidate sequences PCR primers were designed to amplify the
coding region, including the 5 0 initiation codon and the 3 0
termination codon, and included appropriate flanking restriction
enzyme sites. The primers used were TANK (1) 5 0-gctacgca
tatggataaaaacattggc-3 0 (–) 3 0-aagttacctctctgaattcctaggattcga-5 0;
b-transducin (1) 5 0-gacttgcatatgactgagcagatgaccct-3 0 (–) 3 0-
actggtaaccgtgtgcgatcgtatacgacatg – 5 0; RPL7 (1) 5 0-gcactgca
tatggagggtgtagaagagaagaag-3 0 (–) 3 0-gaataatcttcttacttgattgagctcc
taggcgac-5 0; RPL9 (1) 5 0-gcatgacatatgaagactattctcagcaat-3 0 (–)
3 0-caagtcgtccgactacttattcctaggtagcgt – 5 0. PCR products were
then gel purified and cloned into pGEMT-Easy (Promega) and
used to transform competent XL1 blue cells. Positive recombi-
nants were selected on ampicillin plates and plasmid DNA
isolated from 5 ml overnight cultures. The insert was then
released by appropriate restriction digest, gel purified and ligated
in frame to the pET15b vector (Novagen). The ligation mix was
used to transform competent XL1 blue E. coli and where
necessary orientation of the insert confirmed by asymmetric
restriction digestion. Positive pET15b recombinants with the
correct insert in the right orientation were then used to transform
competent BL21(DE3) (Novagen) and selected on LB/ampicillin
agar. Recombinant fusion protein was then expressed by IPTG
induction (1 mm) for 2 h from 50 to 100 ml cultures at
O.D.600  0·4–0·5. Following induction cells were pelleted and
frozen overnight at 2 408C. The following day pellets were
thawed on ice and resuspended in 20 mm Tris pH  7·4
supplemented with 10 mg/ml lysozyme (Sigma)/0·1% Triton
X-100 (Sigma) and incubated at RT for 10 minutes until viscous.
DNA was degraded by the addition of 5 mg/ml DNAse I (Sigma)
and a further 10-minute incubation at RT. Inclusion bodies were
harvested as the insoluble fraction and washed 3 in his-bind
wash buffer (Novagen) supplemented with 0·1% Triton X-100.
The final pellet was resuspended in his-bind buffer containing 6 m
urea and incubated on ice for 1 h. Solubilized proteins were then
harvested from the supernatant following centrifugation and
incubated batchwise with 500 m l his-bind resin (Novagen) for
30 minutes at RT. The resin was then washed 4 in low
stringency wash buffer (Novagen) and bound fusion protein eluted
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in 1 m imidazol. Proteins were quantified using Bradford reagent
(Sigma) and stored at 2 20.
ELISA for his-tagged recombinant fusion proteins
Solubilized fusion protein (,0·5 mg/ml) in 6 m urea/elution
buffer was rapidly diluted to 10 mg/ml in 0·5 m NaCl/20 mm Tris
pH 8·8 and vortexed for 30 s; 100 m l of the diluted protein was
added to each well of a maxisorb immunoplate (Nunc) and
incubated for 6 h at RT. Plates were washed 4 with 200 m l PBS/
0·2% Tween-20 and blocked overnight at 48C in PBS/2% BSA
(Sigma). The following day sera were diluted 1/200 in PBS/0·1%
Tween-20/1% BSA and 100 m l added to each well. Following 1 h
incubation plates were washed 4 with 200 m l PBS/0·2% Tween-
20 and antibody detected with either HRP antihuman IgG, HRP
antihuman IgM diluted 1/1000 or HRP rabbit antihuman IgA, IgG,
IgM (all from Dako) diluted 1/1000. All secondary antibodies
were diluted in PBS/0·1% Tween-20/1% BSA. After 1 h
incubation at RT plates were washed 4 with PBS/0·2%
Tween-20 and antibody binding detected using OPD. O.D. was
measured at 450 nm.
Selection of sera for ELISA
Initial screening was conducted by selecting nine serum samples
from an archive of transplant patients dating back to 1987. For
patients who subsequently developed TxCAD by angiogram
within 5 years ($ 25% luminal thickening in one or more vessels)
sera were selected at or around the time of diagnosis where
available. The mean age of recipients in the TxCAD group was
46·7 years (s.d. 12·0 years). The mean post-transplant elapsed
time at which sera were selected was 24·6 months (s.d.
11·5 months) and sera tested on average 2 months following
diagnosis of TxCAD (s.d. 9·2 months). In some experiments
sequential and pretransplant serum samples were available.
For non-CAD cardiac recipients (no evidence of $ 25%
luminal thickening in donor vessels after 5 years post-transplant),
10 serum samples were selected around 1 year post-transplant
(mean 10 months, s.d. 3·5months). The mean age of the non-CAD
patients was 43·5 years, s.d. 10·4.
Controls
To establish baseline normal range values 11 serum samples from
healthy volunteers were included in all assays, diluted 1/200, and
the positive cut-off threshold set at the mean of these samples
1 two standard deviations.
ELISA for anti-HUVEC antibodies
HUVEC at passage four were plated out at 2·5  104 cells/well on
96-well tissue culture plates (Nunc) in 200 m l of culture medium
consisting of M199 with HEPES (Life Technologies), 2 mm
l-glutamine, 20% FCS, ECGF (Roche Diagnostics), 50 mg/ml
heparin (Sigma) and penicillin and streptomycin. Following
overnight culture confluent HUVEC cultures were washed 3
in 200 m l PBS and fixed with 0·1% glutaraldehyde in PBS for 10
minutes. Free aldehydes were blocked by the addition of 0·05 m
Tris/HCl pH 7·5 for 20 minutes. After a further three washes in
PBS 100 m l of sera was added diluted 1/200 in PBS/0·1% Tween-
20/1% BSA for 45 minutes at RT. Wells were washed with
200 m l PBS/0·2% Tween-20 and 100 m l of the secondary HRP
conjugated antihuman IgG or IgM antibody (Dako), diluted
1/1000 in PBS/0·1% Tween-20/1% BSA, added for a further 45
minutes at RT. After a final three washes in BS/0·2% Tween-20
OPD (Sigma) was added and the reaction stopped with 50 m l 1 m
H2SO4. Plates were read at 450 nm.
RESULTS
Primary immunoscreen
DNA sequencing of immunoreactive clones revealed no overlap
or duplication and in fact produced a diverse list of candidate
antigens which have not yet been described in TxCAD (Table 1).
Table 1. Identity of immunoreactive clones
Clone name[ref.] Protein MW (kDa):pI Identity Region of identity (bp)
M1 [29]
M2 [30]
W1 [31]
W2 [32]
W3
W5 [33]
lysyl tRNA synthetase
TANK
b-transducin
RPL7
Unkown (AL110194)
RPL9
68·034: 5·94
47·799: 5·46
35·077: 7·60
29·266: 10·66
–
21·863: 9·96
94%
99%
99%
99%
99%
98%
1577–1997 (421)
1342–1980 (640)
80–449 (370)
334–810 (475)
351–840 (490)
93–706 (614)
Table 2. Antibody class of positive sera to candidate antigens
Antigen
Antibody
RPL7 RPL9 TANK b -transducin
class CAD Non-CAD CAD Non-CAD CAD Non-CAD CAD Non-CAD
IgM 20% – 100% 67% – 67% – –
IgG 60% – – 33% 33% – 100% 100%
IgM 1 IgG 20% 100% – – 67% 33% – –
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All the clones identified are cytoplasmic, show diverse expression
and are not specific for endothelial cells.
All the clones isolated consisted of truncated sequences
including the coding region and a portion of untranslated region.
BLAST homology searches indicated the identity of the clone
with greater than 90%. Of note, all the truncated clones mapped to
the 3 0 region of expressed mRNA, with the exception of
b -transducin, which mapped to the 5 0 region. One clone, W3
(Table 1) approximately 700 bp matched an unknown cDNA
(GenBank accession number AL110194) with 99% homology.
The next significant match for this sequence was to a human
genomic sequence (GenBank accession number AL031274)
containing a high mobility group protein 1 (HMG1) pseudogene.
Attempts to correlate the sequence of clone W3 with the human
HMG1 sequence (GenBank accession number X12597) showed
no significant similarities. The closest non-human sequence
producing a significant match with clone W3 was pig
HMG1(M21683), which gave 90% identity over 393 base pairs;
however, this region of M21683 (bases 1786–2178) resides
outside the coding sequence (coding sequence 9–656). At present
we are investigating further the nature of clone W3. However, it
should be noted that HMG1 has been reported to be a perinuclear
antineutrophil cytoplasmic antibody (pANCA) autoantigen in
autoimmuine hepatitis [24], rheumatoid arthritis, systemic lupus
erythematosis (SLE), Sjogren’s syndrome (SS), systemic sclerosis
(SS) [25] and ulcerative colitis [26]. Furthermore, there is some
evidence that HMG1 may be expressed on the surface of murine
erythroleukaemia cells and that binding of anti-HMG1 to these
cells can interfere with cell differentiation [27].
None of the genes identified in this screen have been described
previously in TxCAD, and apart from RPL7 have not been
described as antigens in any other disease. The identification of
RPL7 is of particular interest as it has been described as an
autoantigen in systemic lupus erythematosis (SLE) and scler-
oderma with a prevalence of 34% and 41%, respectively [28].
Comparison of the predicted MW and pI of these candidates
(Table 1) with published data on TxCAD antigens identified by
Western blotting shows no clear correlation, although a 46-kDa
band in 17·6% of non-CAD sera was reported [19] which is in the
molecular weight range for TANK. Comparison with 2D-SDS
PAGE analysis shows a potential correlation of a 28-kDa
immunoreactive protein found in TxCAD sera with RPL7
(predicted MW 29·2 kDa). In this study [20] the 28 kDa band
was resolved into four spots, three of which were identified
as triose-phosphate isomerase (predicted MW 26·5 kDa). It
should, however, be noted that the isoelectric resolving range
in these studies (pH 4–7) did not include proteins in the
region of pI 10–11.
0 10 20 30 40 50
O
.D
.
0·0
0·1
0·2
0·3
0·4
0·5
0·6
*
*
*
(a)
Weeks post - Tx
10 20 30 40 50
0·0
0·1
0·2
0·3
0·4
0·5
0·6
0
O
.D
.
*
*
(b)
Fig. 2. Anti-RPL7 (a) and anti-HUVEC cell surface antibodies (b) were
measured by ELISA using stored sequential sera from a patient who
developed RPL7 antibodies following transplantation. A significant
increase in both anti-RPL7 and anti-HUVEC antibodies is seen at week
17 during which time the patient suffered a rejection episode. At 44 weeks
post-transplant levels of anti-HUVEC antibodies have receded to
pretransplant levels although anti-RPL7 (IgG) are significantly elevated.
This patient was diagnosed with CAD at week 56. The normal O.D. range
for anti-RPL7 antibodies in this experiment was IgG 0·175 (s.d. 0·043)
IgM 0·166 (s.d. 0·037) and for anti-HUVEC IgG 0·190 (s.d. 0·037) IgM
0·163 (s.d. 0·055). Asterisks indicate a significant increase in O.D. relative
to pretransplant levels (P , 0·05 Student’s t-test). O, IgG; X, IgM.
P , 0·05 t-test.
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Fig. 1. The percentage of patients in each group showing positive
immunoreactivity to each of the candidate antigens is shown. Sera were
judged as positive when the mean O.D. of duplicate wells exceeded the
mean plus two standard deviations of a normal range of control sera
(n  11) run in parallel with the assay. A significant association of
immuno-reactivity to RPL7 and the presence of CAD is indicated by the
asterisk (Fisher’s exact test P , 0·05). B, CAD (n  9); B, non-CAD
(n  10). *P , Fisher’s exact test.
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ELISA screening
Recombinant his-tagged fusion proteins for TANK, b -transducin,
RPL7 and RPL9 were constructed for further study using the
pET15b vector (Novagen) and purified as inclusion bodies using
nickel affinity chromatography. Prevalence of seropositivity
among the CAD and non-CAD groups is shown in Fig. 1. The
highest prevalence in the CAD group was to RPL7 (55·6%) and
showed a significant association with the disease when compared
to the non-CAD group (10%; P , 0·05 Fisher’s exact test). In the
non-CAD group the highest prevalence was to RPL9 (42·9%),
although levels were similar to the CAD group (50·0%).
Prevalence to the remaining antigens could be measured, although
no clear distinction between CAD and non-CAD groups could be
found. For RPL7 the majority of CAD sera (60%) were IgG
positive with 20% showing either IgM or IgG/IgM reactivity
(Table 2). In the non-CAD group only one serum (IgG and IgM)
showed reactivity to RPL7. Notably, in the CAD group 100% of
anti-RPL9 positive sera were IgM whereas 67% of the non-CAD
group were IgM and 33% IgG. Binding of CAD sera to RPL7
showed a 2·010 ^ 0·910 s.d. (IgG) and 1·897 ^ 0·202 (IgM)-fold
increase above the mean O.D. value for the normal range. Average
O.D. values for normal control sera were between 0·246 and 0·625
(IgG) and 0·342–0·593 (IgM).Two patients who tested positive for
RPL7 antibodies in this initial screen were selected to determine
whether the antibody was present or absent prior to transplantation.
In one patient RPL7 antibodies were absent prior to transplantation
(see Fig. 2a). Notably, RPL7 antibodies were present in the other
patient (data not shown), indicating clearly that in some cases
these antibodies may be present prior to transplantation. Whether
the presence of these antibodies correlates with pretransplant
diagnosis is currently under investigation.
Sequential sera and correlation with AECA
The presence of antibody to self-components may be only
associated with disease if there is a correlation between antibody
titre and disease activity. One patient with TxCAD and RPL7
antibodies was selected and sequential sera identified from the
first year following transplantation. Anti-RPL7 and anti-HUVEC
antibodies (IgG and IgM) were assayed in parallel (Fig. 2a). This
patient was negative for RPL7 prior to transplantation, compared
to normal sera. At 17 weeks following transplantation anti-RPL7
antibodies (both IgG and IgM) were significantly elevated
compared to pretransplant levels (Fig. 2a). During this period
the patient experienced a rejection episode which resolved with
immunosuppression. At 24 weeks post-transplantation anti-RPL7
levels receded to those comparable with pretransplant. At
44 weeks post-transplant, levels of anti-RPL7 again increased
significantly (IgG but not IgM) compared to pretransplant levels.
At the 1-year angiography this patient was diagnosed with
TxCAD (. 25% arterial stenosis).
Although fluctuations in anti-RPL7 antibodies apparently
correlated with anti-HUVEC antibodies (IgG and IgM) at
17 weeks (Fig. 2b), this was not seen at 44 weeks. At 17 weeks
a significant increase in anti-HUVEC antibodies (IgG and IgM)
was seen, compared to pretransplant levels which also receded
following the rejection episode. However, at 44 weeks when anti-
RPL7 antibodies had risen again, levels of anti-HUVEC
antibodies were still at levels comparable to pretransplant.
In summary, significant increases in IgG and IgM anti-RPL7
antibodies appeared in this patient following transplantation,
which correlated with the onset and remission of a single rejection
episode. Following this period the patient developed increased
IgG anti-RPL7 antibody levels which preceded the diagnosis of
TxCAD. These fluctuations in anti-RPL7 antibodies do not
correlate with anti-HUVEC antibodies.
DISCUSSION
This study set out to evaluate the applicability of expression
cloning for the identification of candidate antigens associated with
TxCAD. This method offers several advantages over proteomic
analysis in that candidate immunoreactive antigens can be
identified from clonal precursors and screened rapidly to
homogeneity for identification by DNA sequencing and database
homology searches. The disadvantages of the technique are that
elimination of antigens which are common to both TxCAD and
non-CAD transplant recipients is problematic and can only be
performed reliably following production of recombinant antigen
and serological investigations by ELISA. Furthermore, expression
in a prokaryotic system will exclude antigen/antibody interactions
dependent on eukaryotic specific glycosylation. None the less, we
were successful in identifying six immunoreactive clones of which
one, RPL7, showed a significant association with TxCAD. The
identification of this antigen as a significant autoantigen in SLE
and scleroderma [28] raises the possibility that TxCAD may share
immunological aspects of autoimmune mixed connective tissue
disease. In the study by Neu et al. attempts to correlate anti-RPL7
titre with clinical features of SLE identified a potential negative
correlation with vasculitis and lung fibrosis. However, the
inclusion of cardiovascular involvement, a known risk association
with SLE which may represent a fivefold increased risk [29], was
not included in this study.
At least 75 ribosomal proteins have been identified so far and
it has been estimated that in total they constitute approximately
10% of the cell mass [30]. Consequently it has been mooted that
the appearance of antibodies to these proteins reflects the
abundance of antigen available for immune activation. The
majority of the ribosomal proteins show a cytoplasmic localiza-
tion; RPL7, however, is one of the few ribosomal proteins to also
be found in the nucleus. Furthermore, in this study we also
identified RPL9 as a candidate antigen but, although prevalent in
both CAD and non-CAD groups, did not show the same degree of
specificity for TxCAD as RPL7. A similar discordance between
antibodies to RPL7 and the classical lupus ribosomal P protein has
been noted in SLE [28]. These findings would suggest that distinct
mechanisms other than mass action effects may operate in the
sensitization to RPL7. In support of this, studies on apoptotic
keratinocytes have identified the presence of fragmented en-
doplasmic reticulum and ribosomes in a population of cell surface
blebs [31]. This demonstrates that cytosolic/nuclear antigens may
be reorganized during apoptosis and potentially influence the
manner in which the immune system detects and processes these
antigens. Recently a macrophage receptor specific for negatively
charged phospholipids exposed on the outer leaflet of apoptotic
cells has been cloned [32]. It is likely that macrophages will detect
these expressed on the outer membrane of blebs, which are rich in
endoplasmic reticulum and ribosomes. Whether these bleb
structures are processed in a particular antigenic form remains
to be elucidated.
Several groups have examined the potential role of the related
ribosomal protein P0 antigen in the pathogenesis of SLE. Affinity
purified antiribosomal P0 antibodies have been reported to bind
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the surface of HUVEC [33–38] and plasma membranes of
hepatoma cells [39], although this latter study did not differentiate
between the cell surface membrane and endoplasmic reticulum.
Furthermore, antiribosomal P0 antibodies have been reported to
penetrate live hepatocytes and cause inhibition of protein
synthesis [40], although it should be noted that the levels of
antibodies used in these studies (5–10 mg/ml) would suggest that
the effect is likely to be mediated by passive mechanisms rather
than specific antigen/antibody interactions. The results reported in
this study do not support a role for cell surface expression of
RPL7, as AECA staining did not correlate with RPL7 titre in
patient sera.
The prevalence of the remaining antigens identified in this
study indicates the presence of antibody titres in excess of that
seen in the normal population in cardiac transplant recipients
irrespective of whether they develop TxCAD. The appearance of
common antibodies to other proteins has been reported previously
in CAD and non-CAD groups and suggests that these specificities
occur as a consequence of transplantation, due presumably to the
release of cytoplasmic antigens in the context of trauma induced
inflammation during and after surgery. The lack of a correlation of
these other antigens with TxCAD would suggest, therefore, that
sensitization to RPL7 may either predispose a proportion of those
recipients with pre-existing antibodies, or those who develop them
following surgery, to the disease. Currently there is controversial
evidence concerning the potential role of these antibodies directly
in the pathogenesis of the disease. Alternative considerations
regarding the association of these antibodies are likely to reflect
distinct cellular and immunological pathomechanisms specific to
this disease process.
In animal models sensitization to cardiac myosin accelerates
rejection in an organ-specific manner [41]. Although RPL7 shows
a diverse tissue expression the association of anti-RPL7 with
vascular disease in SLE and scleroderma may be consistent with
the vascular anomalies observed in TxCAD. Clonal expansion of
RPL7 specific B cells may potentiate the capture of antigen
released from damaged endothelium via B cell surface Ig. In line
with this is the known association of acute rejection episodes with
TxCAD [17]. The relative lack of RPL7 antibodies in the non-
CAD group may therefore reflect less endothelial cell damage.
A further consideration in the context of allotransplantation is
the possibility that RPL7 may act as a minor histocompatibility
antigen. There are currently five sequences for this gene in the
database which by comparison show single nucleotide substitu-
tions. These are sufficient to cause amino acid changes which may
enable them to be perceived as non-self if they are present in the
donor organ. We are currently investigating by SSCP whether
polymorphisms can be identified for this gene.
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